Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While LL-37 acts as a broad-spectrum antimicrobial and immunomodulatory peptide involved in host defense and wound repair, but can also promote inflammation and cancer cell proliferation in some contexts5215, Tirzepatide is approved for type 2 diabetes and obesity, producing larger HbA1c and body-weight reductions than semaglutide in head-to-head trials24.
While LL-37 works as a cationic amphipathic 37-amino-acid cathelicidin peptide generated from hCAP18 that disrupts microbial membranes and modulates innate immunity, including chemotaxis, cytokine induction, and NET formation521586, Tirzepatide is a 39-amino-acid synthetic peptide primarily based on GIP sequence with C20 fatty diacid conjugation that acts as a dual agonist at GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite24.
LL-37
CAMP
Tirzepatide
Not assigned in the current dataset.
LL-37 and Tirzepatide are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: LL-37 is more often discussed in the realm of Immunology and inflammation and Gastroenterology, whereas Tirzepatide is more often associated with the realm of Metabolic and endocrine and Cardiovascular health. They also influence different molecular systems, with LL-37 tracking more closely to GPCR receptor while Tirzepatide centers more on GLP-1 receptor. LL-37 has a more natural endogenous origin, while Tirzepatide is closer to synthetic analog background and their development context also differs, with LL-37 in Preclinical development while Tirzepatide is approved. LL-37 takes the form of a linear peptide, whereas Tirzepatide is closer to a peptide conjugate, while Tirzepatide incorporates lipidation and d-amino acid substitution features that are not part of LL-37.